A citation-based method for searching scientific literature

Jorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D le Coutre, Ronald Paquette, Charles Chuah, Franck E Nicolini, Jane F Apperley, H Jean Khoury, Moshe Talpaz, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M Rivera, Frank G Haluska, François Guilhot, Michael W Deininger, Andreas Hochhaus, Timothy P Hughes, Neil P Shah, Hagop M Kantarjian. Blood 2018
Times Cited: 249







List of co-cited articles
740 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
A Hochhaus, M Baccarani, R T Silver, C Schiffer, J F Apperley, F Cervantes, R E Clark, J E Cortes, M W Deininger, F Guilhot,[...]. Leukemia 2020
453
37

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
J E Cortes, D-W Kim, J Pinilla-Ibarz, P le Coutre, R Paquette, C Chuah, F E Nicolini, J F Apperley, H J Khoury, M Talpaz,[...]. N Engl J Med 2013
707
36

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Jorge E Cortes, Giuseppe Saglio, Hagop M Kantarjian, Michele Baccarani, Jiří Mayer, Concepción Boqué, Neil P Shah, Charles Chuah, Luis Casanova, Brigid Bradley-Garelik,[...]. J Clin Oncol 2016
496
34

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Timothy P Hughes, Michael J Mauro, Jorge E Cortes, Hironobu Minami, Delphine Rea, Daniel J DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus,[...]. N Engl J Med 2019
152
30

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Andreas Hochhaus, Richard A Larson, François Guilhot, Jerald P Radich, Susan Branford, Timothy P Hughes, Michele Baccarani, Michael W Deininger, Francisco Cervantes, Satoko Fujihara,[...]. N Engl J Med 2017
626
28

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Jorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, Michael J Mauro, Charles Chuah, Dong-Wook Kim, Irina Dyagil, Nataliia Glushko, Dragana Milojkovic, Philipp le Coutre,[...]. J Clin Oncol 2018
233
25

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
A Hochhaus, G Saglio, T P Hughes, R A Larson, D-W Kim, S Issaragrisil, P D le Coutre, G Etienne, P E Dorlhiac-Llacer, R E Clark,[...]. Leukemia 2016
478
24

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H Lipton, Charles A Schiffer,[...]. Blood 2021
35
68

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
Hannah Bower, Magnus Björkholm, Paul W Dickman, Martin Höglund, Paul C Lambert, Therese M-L Andersson. J Clin Oncol 2016
430
22

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Hagop M Kantarjian, Timothy P Hughes, Richard A Larson, Dong-Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E Clark,[...]. Leukemia 2021
67
32

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Thomas O'Hare, William C Shakespeare, Xiaotian Zhu, Christopher A Eide, Victor M Rivera, Frank Wang, Lauren T Adrian, Tianjun Zhou, Wei-Sheng Huang, Qihong Xu,[...]. Cancer Cell 2009
839
20


The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, Sandra W Cowan-Jacob, Alice Loo, Pascal Furet, Andreas L Marzinzik, Xavier Pelle, Jerry Donovan, Wenjing Zhu,[...]. Nature 2017
275
17

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Delphine Réa, Michael J Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Andre Abdo,[...]. Blood 2021
54
31

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, Franck E Nicolini, Philipp le Coutre, Richard E Clark,[...]. Lancet Oncol 2016
155
16

Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, Dale Bixby, Michael J Mauro, Ian Flinn, Thomas O'Hare, Simin Hu, Narayana I Narasimhan, Victor M Rivera,[...]. N Engl J Med 2012
525
16

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.
David J Dorer, Ronald K Knickerbocker, Michele Baccarani, Jorge E Cortes, Andreas Hochhaus, Moshe Talpaz, Frank G Haluska. Leuk Res 2016
96
16

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Giuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Clarisse Lobo, Ricardo Pasquini, Richard E Clark, Andreas Hochhaus, Timothy P Hughes,[...]. N Engl J Med 2010
14

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Kiran Naqvi, Elias Jabbour, Jeffrey Skinner, Kristin Anderson, Sara Dellasala, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado,[...]. Cancer 2020
57
22

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Elias Jabbour, Nicholas J Short, Farhad Ravandi, Xuelin Huang, Naval Daver, Courtney D DiNardo, Marina Konopleva, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero,[...]. Lancet Haematol 2018
124
13

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
Koji Sasaki, Sara S Strom, Susan O'Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Preetesh Jain,[...]. Lancet Haematol 2015
171
12

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy Hughes,[...]. N Engl J Med 2003
12

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop Kantarjian, Neil P Shah, Andreas Hochhaus, Jorge Cortes, Sandip Shah, Manuel Ayala, Beatriz Moiraghi, Zhixiang Shen, Jiri Mayer, Ricardo Pasquini,[...]. N Engl J Med 2010
12

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Michele Baccarani, Michael W Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F Apperley, Francisco Cervantes, Richard E Clark, Jorge E Cortes, François Guilhot,[...]. Blood 2013
11

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Moshe Talpaz, Neil P Shah, Hagop Kantarjian, Nicholas Donato, John Nicoll, Ron Paquette, Jorge Cortes, Susan O'Brien, Claude Nicaise, Eric Bleickardt,[...]. N Engl J Med 2006
11



European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre,[...]. Leukemia 2016
276
11

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Christopher A Eide, Matthew S Zabriskie, Samantha L Savage Stevens, Orlando Antelope, Nadeem A Vellore, Hein Than, Anna Reister Schultz, Phillip Clair, Amber D Bowler, Anthony D Pomicter,[...]. Cancer Cell 2019
88
12

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Robin Foà, Renato Bassan, Antonella Vitale, Loredana Elia, Alfonso Piciocchi, Maria-Cristina Puzzolo, Martina Canichella, Piera Viero, Felicetto Ferrara, Monia Lunghi,[...]. N Engl J Med 2020
143
11

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
R Hehlmann, M Lauseker, S Saußele, M Pfirrmann, S Krause, H J Kolb, A Neubauer, D K Hossfeld, C Nerl, A Gratwohl,[...]. Leukemia 2017
144
10

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, Silvia Buonamici, Simona Cotesta, Sandra W Cowan-Jacob, Stephanie Dodd, Peter Drueckes, Doriano Fabbro, Tobias Gabriel,[...]. J Med Chem 2018
160
10

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Preetesh Jain, Hagop Kantarjian, Prajwal C Boddu, Graciela M Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M Kadia, Princy Sam,[...]. Blood Adv 2019
59
15

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
François-Xavier Mahon, Delphine Réa, Joëlle Guilhot, François Guilhot, Françoise Huguet, Franck Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet,[...]. Lancet Oncol 2010
9

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Adele K Fielding, Jacob M Rowe, Georgina Buck, Letizia Foroni, Gareth Gerrard, Mark R Litzow, Hillard Lazarus, Selina M Luger, David I Marks, Andrew K McMillan,[...]. Blood 2014
242
9

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Robin Foà, Antonella Vitale, Marco Vignetti, Giovanna Meloni, Anna Guarini, Maria Stefania De Propris, Loredana Elia, Francesca Paoloni, Paola Fazi, Giuseppe Cimino,[...]. Blood 2011
308
9

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Neil P Shah, Philippe Rousselot, Charles Schiffer, Delphine Rea, Jorge E Cortes, Jorge Milone, Hesham Mohamed, Diane Healey, Hagop Kantarjian, Andreas Hochhaus,[...]. Am J Hematol 2016
103
8

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Andreas Hochhaus, Carlo Gambacorti-Passerini, Camille Abboud, Bjørn Tore Gjertsen, Tim H Brümmendorf, B Douglas Smith, Thomas Ernst, Pilar Giraldo-Castellano, Ulla Olsson-Strömberg, Susanne Saussele,[...]. Leukemia 2020
27
29

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Abhishek Maiti, Miguel J Franquiz, Farhad Ravandi, Jorge E Cortes, Elias J Jabbour, Koji Sasaki, Kayleigh Marx, Naval G Daver, Tapan M Kadia, Marina Y Konopleva,[...]. Acta Haematol 2020
34
23

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Jorge E Cortes, Dong-Wook Kim, Hagop M Kantarjian, Tim H Brümmendorf, Irina Dyagil, Laimonas Griskevicius, Hemant Malhotra, Christine Powell, Karïn Gogat, Athena M Countouriotis,[...]. J Clin Oncol 2012
305
8


Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Jorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, Jeff H Lipton, Dong-Wook Kim, Philippe Schafhausen, Ewa Matczak, Eric Leip, Kay Noonan, Tim H Brümmendorf,[...]. Am J Hematol 2016
56
14

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Michele Baccarani, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger,[...]. Blood 2006
914
8

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
Rita Assi, Hagop Kantarjian, Nicholas J Short, Naval Daver, Koichi Takahashi, Guillermo Garcia-Manero, Courtney DiNardo, Jan Burger, Jorge Cortes, Nitin Jain,[...]. Clin Lymphoma Myeloma Leuk 2017
103
8

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Elias Jabbour, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Xuelin Huang, Stefan Faderl, Naveen Pemmaraju, Naval Daver, Guillermo Garcia-Manero, Koji Sasaki,[...]. Lancet Oncol 2015
178
8

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
M Pfirrmann, M Baccarani, S Saussele, J Guilhot, F Cervantes, G Ossenkoppele, V S Hoffmann, F Castagnetti, J Hasford, R Hehlmann,[...]. Leukemia 2016
154
8

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Preetesh Jain, Hagop M Kantarjian, Ahmad Ghorab, Koji Sasaki, Elias J Jabbour, Graciela Nogueras Gonzalez, Rashmi Kanagal-Shamanna, Ghayas C Issa, Guillermo Garcia-Manero, Devendra Kc,[...]. Cancer 2017
79
10

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Susanne Saussele, Johan Richter, Joelle Guilhot, Franz X Gruber, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen J W M Janssen, Jiri Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis,[...]. Lancet Oncol 2018
304
8

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
E Hadzijusufovic, K Albrecht-Schgoer, K Huber, G Hoermann, F Grebien, G Eisenwort, W Schgoer, S Herndlhofer, C Kaun, M Theurl,[...]. Leukemia 2017
74
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.